argenx SE and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends: Argenx SE vs. Rhythm Pharmaceuticals, Inc.

In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Argenx SE and Rhythm Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Argenx SE's SG&A expenses surged by an impressive 16,600%, reflecting its aggressive expansion and strategic investments. In contrast, Rhythm Pharmaceuticals, Inc. experienced a 9,600% increase, indicating a more measured growth approach.

Key Insights

• 2014-2018: Both companies maintained modest spending, with Argenx SE slightly ahead.
• 2019-2023: Argenx SE's expenses skyrocketed, peaking at 709 million in 2023, nearly six times that of Rhythm Pharmaceuticals.

These trends highlight Argenx SE's rapid scaling efforts, while Rhythm Pharmaceuticals focuses on steady growth. Investors and industry analysts should consider these patterns when evaluating future prospects.